Stephanotis can inhibit the proliferation of the new coronavirus and is expected to have strong market demand in the future

Stephanatine, also known as stephanatine, mainly appears as white crystals with a molecular formula of C37H38N2O6. Stephanatine has the effect of promoting the proliferation of bone marrow tissue and increasing the number of white blood cells in the human body. It is mainly used as a white blood cell growth drug and is active in the medical field.

Stephanotis is mainly derived from roots that are not tolerated by the soil. Dibong is a perennial herbaceous vine of the genus Stephanotis in the family Fangjiaceae, and its root tuber is a traditional Chinese medicine in my country. Our country is rich in land resources, mostly distributed in southwestern regions such as Yunnan, Sichuan, and Guizhou. The rich raw materials have laid a good foundation for the development of the stephanote industry.

In 1934, Japanese scientists first extracted stephanatine from Diphenosa. Since then, stephanatine has been mainly used as a leukocyte growth drug and used in the clinical treatment of agranulocytosis caused by tumor chemotherapy and radiotherapy and leukopenia caused by other reasons. . Stephanatine has the effects of enhancing human immunity, increasing the sensitivity of tumor cells to drugs, and activating macrophages in the human body, and is expected to be used in the development of anti-tumor drugs.

According to the “2023-2028 China Stephanate Industry Market In-depth Research and Development Prospects Forecast Report released by the Industrial Research Center, After the outbreak of the new coronavirus, new coronavirus treatment drugs have become the focus of research in the pharmaceutical industry. In 2020, Chinese scientists experimentally found that stephanatine has a better inhibitory effect on the new coronavirus. 10 μM (micromol/L) of stepfootin is enough to inhibit the replication of the coronavirus 15,393 times. Even a small amount of stepfootin can inhibit the self-replication of the coronavirus. , thereby alleviating the condition of COVID-19. Later, the American “Science” magazine also published a paper stating that stephanatine is more effective in treating COVID-19 than well-known COVID-19 drugs such as remdesivir and Parovide. On May 10, 2022, a new COVID-19 treatment drug with stephanatine as the main active ingredient, led by Chinese scientists, was authorized by the national invention patent.

Currently, there is only one production process for stephanatine, which involves wetting, leaching, extraction, drying, distillation, purification, precipitation, concentration, etc. It has many steps, cumbersome operations, long production cycle, and low product yield. Lower disadvantages are not conducive to large-scale industrial production. Therefore, the output of stephanotisin in my country is low and the price is high. The market quotation is generally more than 60 yuan per gram. The production process of stephanatine needs to be improved urgently.

At present, there are only a small number of stephanatine production companies in my country, mainly including Yunnan Phytozoa Biotechnology Co., Ltd., Hubei Weideli Chemical Technology Co., Ltd., Shanghai Lianmai Bioengineering Co., Ltd., etc. At the same time, stephanotisin has also received attention from the academic community. Well-known research institutes such as Hebei University, Tianjin University of Traditional Chinese Medicine, and China University of Chemical Technology have established research projects related to stepheniacetin. Industryanalysts said that as the academic community continues to deepen its research on stephanatine, its application value has been developed and applied, and the market Demand will continue to rise.